Recommendation of the President – Trimbow (beclometasone, formoterol, glycopyrronium bromide)
On 16 May 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 62/2025 on the appraisal of drug Trimbow (beclometasone, formoterol, glycopyrronium bromide) in indications: maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) in whom adequate therapeutic effect is not achieved with concomitant use of an inhaled corticosteroid and a long-acting beta-2 receptor agonist or with concomitant use of a long-acting beta-2 receptor agonist and a long-acting muscarinic receptor antagonist.